Bioavailability and pharmacokinetic studies in the development of an oral formulation of stobadine dipalmitate

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 21, Issue 7, 1999, Pages 499-503

  Bauerová, Katarína ^a   Bohov, P ^b   Durisova M ^b   Bezek, S ^b  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Antioxidant; Bioequivalence; Complex Tools for Linear Dynamic System Analysis (CXT); GC MS; Pyridoindole; Stobadine

Indexed keywords

ANTIOXIDANT; STOBADINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG HALF LIFE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CAPSULES; CARBOLINES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; THERAPEUTIC EQUIVALENCY;

EID: 0032887816     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Štolc, S. et al. Medicine with antiarrhythmic and antihypoxic activity and its method of preparation. Patents: CS 229067, SE. 8204693-9, BE 894148, CH 651754, BRD P-3231088, ES 553017, JP 1514040, 1983.
2. Horáková, L'., Štolc, S. Review: Antioxidant and pharmacodynamic effects of pyridoindole stobadine. Gen Pharmac 1998; 30: 627-38.
3. Kállay, Z. et al. Plasma concentration, tissue distribution and excretion of the prospective cardioprotective agent cis-(-)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido-[4,3-b]indole dihydrochloride in rats. Arzneim-Forsch/Drug Res 1990, 40: 974-9.
4. Kállay, Z. et al. Pharmacokinetics of stobadine and of the sum of its metabolites in rats during repeated administration. Biopharm Drug Dispos 1991, 12: 201-5.
5. 3H-labelled stobadin in rat plasma for pharmacokinetic purposes. Pharmazie 1991, 45: 437-8.
6. Bezek, Š. et al. Stobadine bioavailability in dogs (in Slovak). Cs Fyziol 1988, 37: 240.
7. Šoltés, L. et al. A high-performance liquid chromatographic method for the determination of stobadin pharmacokinetics in serum. Biopharm Drug Dispos 1991, 12: 29-35.
8. Kukan, M. et al. On the absorption of drugs using chronic dog ileal loop method. Methods Find Exp Clin Pharmacol 1994, 16: 437-42.
9. Bauerová, K. et al. Evaluation of relative bioavailability of two stobadine preparations in dogs. Ther Drug Monit [Int Congr Ther Drug Monitoring Clin Toxicol (September 4-8, Vienna) 1995] 1995, 17: 423.
10. Dedik, L., Durišová, M. Frequency response method in pharmacokinetics. J Pharmacokin Biopharm 1994, 22: 293-307.
11. Durišová, M., Dedík, L. Comparative study of human pentacaine pharmacokinetics in time and frequency domain. Methods Find Exp Clin Pharmacol 1994, 16: 219-32.
12. Dedík, L., Durišová, M. CXT: A programme for analysis of linear dynamic systems in the frequency domain. Int J Biomed Comput 1995, 39: 231-41.
13. Akaike, H. Modern development of statistical methods. In: Trends and Progress in System Identification. Eykhoff, P. (Ed.). Pergamon Press: Oxford 1981, 1-345.
14. 3H]stobadine in biological material. J Radioanal Nucl Chem 1987, 111: 117-22.
15. Marko, V. Spectrofluorometric analysis in biological fluids of the dihydrochloride of (-)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1-H-pyrido[4,3b]-indole (DH 1011), a prospective antiarrhythmic. Pharmazie 1985, 40: 192.
16. Šasnár, V. et al. Fluorimetric assay of stobadine in serum of dogs. J Pharm Biomed Anal 1989, 7: 1207-12.
17. Marko, V. Determination of stobadine, a novel cardioprotective drug, using capillary gas chromatography with nitrogen-phosphorus detection after selective solid-phase extraction from serum. J Chromatogr 1988, 433: 269-75.
18. Majercik, M. et al. Six-month toxicology study of the substance DP 1031 in beagle dogs. Cs Fyziol 1984, 33: 171.
19. max for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1991, 29: 394-9.
20. Lacey, L.F. et al. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci 1994, 83: 212-5.
21. max/AUC is an effective metric in investigation of bioequivalence. Pharm Res 1995, 12: 937-42.